Evidence map›Paper›PMID 24942396›Full record

ArticleClinical pharmacology and therapeutics2014

Patients benefit from genetics-guided coumarin anticoagulant therapy.

A H Maitland-van der Zee, A K Daly, F Kamali, V G Manolopoulous, V G Manolopoulos, T I Verhoef, M Wadelius, A de Boer, M Pirmohamed, EU-PACT Study Group

Erratum issuedAbstract readComment
PubMed Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2016
    Article
  3. Article
  4. Clinical Perspectives on Targeting Therapies for Personalized Medicine.Advances in protein chemistry and structural biology · 2016
    Review
  5. Genes affecting warfarin response-interactive or additive?Journal of clinical pharmacology · 2015
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

A H Maitland-van der ZeeDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
A K DalyInstitute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, UK.
F KamaliInstitute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, UK.
V G Manolopoulous
V G ManolopoulosLaboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
T I VerhoefDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
M WadeliusDepartment of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden.
A de BoerDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
M PirmohamedThe Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
EU-PACT Study Group

Funding

Medical Research Council MR/L006758/1
6 · The paper itself

Abstract

Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings.

Indexed as

AlgorithmsGenotypeAcenocoumarolAnticoagulantsAryl Hydrocarbon HydroxylasesBlood CoagulationFemaleHumansMaleMixed Function OxygenasesPhenprocoumonVitamin K Epoxide ReductasesWarfarinAcenocoumarolAnticoagulantsAryl Hydrocarbon HydroxylasesMixed Function OxygenasesPhenprocoumonVitamin K Epoxide ReductasesWarfarin

Identifiers

PMID24942396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.